Advertisement

Alternative switching strategies based on regimens with a low genetic barrier: do clinicians have a choice nowadays?

  • Jesús TroyaEmail author
  • Pablo Ryan
  • Rocío Montejano
  • Alfonso Cabello
  • Guillermo Cuevas
  • Mariano Matarranz
  • Irene Cañamares
  • Javier Solís
  • Luis Álvarez-Sala Walther
Review
  • 21 Downloads

Abstract

Clinicians sometimes use switching strategies based on regimens such as RAL + ABC/3TC or RPV + ABC/3TC in order to resolve tolerability or safety issues associated with conventional recommended first-line strategies. Despite the low genetic barrier of these regimens, high safety and efficacy rates have been reported in retrospective studies.

Keywords

Switching Raltegravir Rilpivirine Abacavir/lamivudine Safety Efficacy 

Notes

Compliance with ethical standards

Conflicts of interest

The authors declare that they have no conflicts of interest.

Ethical approval

Ethical approval has not been necessary as this article is based on a review of published data.

Informed consent

Informed consent has not been necessary as this article is based on a review of published data.

References

  1. 1.
    European Guidelines for treatment of HIV-infected adults in Europe. Guidelines version 9.0. European AIDS Clinical Society (EACS), October, 2017. Available at: http://www.eacsociety.org/files/guidelines_9.0-english.pdf. (Accessed August 2018)
  2. 2.
    Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services USA. Available at: https://aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf.pdf. (Accessed August 2018)
  3. 3.
    Raltegravir (Edurant®). Data sheet available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022145s004lbl.pdf (Accessed August 2018)
  4. 4.
    Rilpivirine (Issentress®). Data sheet available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022145s004lbl.pdf (Accessed August 2018)
  5. 5.
    Rasmussen TA, Jensen D, Tolstrup M, Nielsen US, Erlandsen EJ, Birn H, Ostergaard L, Langdahl BL, Laursen AL (2012) Comparison of bone and renal effects in HIV-infected adults switching to abacavir or tenofovir based therapy in a randomized trial. PLoS One 7(3):e32445.  https://doi.org/10.1371/journal.pone.0032445 CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Stellbrink HJ, Orkin C, Arribas JR, Compston J, Gerstoft J, Van Wijngaerden E, Lazzarin A, Rizzardini G, Sprenger HG, Lambert J, Sture G, Leather D, Hughes S, Zucchi P, Pearce H, ASSERT Study Group (2010) Comparison of changes in bone density and turnover with abacavir-lamivudine versus tenofovir-emtricitabine in HIV infected adults: 48-week results from the ASSERT study. Clin Infect Dis 51:963–972.  https://doi.org/10.1086/656417 CrossRefPubMedGoogle Scholar
  7. 7.
    Curran A, Rojas J, Cabello A, Troya J, Imaz A, Domingo P, Martinez E, Ryan P, Górgolas M, Podzamczer D, Knobel H, Gutiérrez F, Ribera E (2016) Effectiveness and safety of an abacavir/lamivudine + rilpivirine regimen for the treatment of HIV-1 infection in naive patients. J Antimicrob Chemother 71(12):3510–3514.  https://doi.org/10.1086/656417 CrossRefPubMedGoogle Scholar
  8. 8.
    Raffi F, Jaeger H, Quiros-Roldan E, Albrecht H, Belonosova E, Gatell JM, Baril JG, Domingo P, Brennan C, Almond S, Min S, extended SPRING-2 Study Group (2013) Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naïve adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, double-blind, non-inferiority trial. Lancet Infect Dis 13(11):927–935.  https://doi.org/10.1016/S1473-3099(13)70257-3 CrossRefPubMedGoogle Scholar
  9. 9.
    Troya J, Ryan P, Ribera E, Podzamczer D, Hontañón V, Terrón JA, Boix V, Moreno S, Barrufet P, Castaño M, Carrero A, Galindo MJ, Suárez-Lozano I, Knobel H, Raffo M, Solís J, Yllescas M, Esteban H, González-García J, Berenguer J, Imaz A (2016) Abacavir/lamivudine plus rilpivirine is an effective and safe strategy for HIV-1 suppressed patients: 48 week results of the SIMRIKI retrospective study. PLoS One 11(10):e0164455.  https://doi.org/10.1371/journal.pone.0164455 CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Palacios R, Pérez-Hernández IA, Martínez MA, Mayorga ML, González-Domenech CM, Omar M, Olalla J, Romero A, Romero JM, Pérez-Camacho I, Hernández-Quero J, Santos J (2016) Efficacy and safety of switching to abacavir/lamivudine (ABC/3TC) plus rilpivirine (RPV) in virologically suppressed HIV-infected patients on HAART. Eur J Clin Microbiol Infect Dis 35(5):815–819.  https://doi.org/10.1007/s10096-016-2602-3 CrossRefPubMedGoogle Scholar
  11. 11.
    Marshall N, Hedley L, Smith C, Swaden L, Tsintas R, Edwards S, Waters L, Johnson M (2014) Is switching to Kivexa with rilpivirine as effective as switching to Eviplera in clinical practice? HIV Med 17(Suppl. 1):19.  https://doi.org/10.1111/hiv.12393 CrossRefGoogle Scholar
  12. 12.
    Galizzi N, Galli L, Poli A, Gianotti N, Carini E, Bigoloni A, Tambussi G, Nozza S, Lazzarin A, Castagna A, Mancusi D, Termini R (2018) Long-term efficacy and safety of rilpivirine plus abacavir and lamivudine in HIV-1 infected patients with undetectable viral load. PLoS One 13(2):e0191300.  https://doi.org/10.1371/journal.pone.0191300 CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Martínez E, Larrousse M, Llibre JM, Gutiérrez F, Saumoy M, Antela A, Knobel H, Murillas J, Berenguer J, Pich J, Pérez I, Gatell JM, SPIRAL Study Group (2010) Substitution of raltegravir for ritonavir-boosted protease inhibitors in HIV-infected patients: the SPIRAL study. AIDS 24(11):1697–1707.  https://doi.org/10.1097/QAD.0b013e32833a608a CrossRefPubMedGoogle Scholar
  14. 14.
    Fabbiani M, Mondi A, Colafigli M, D'Ettorre G, Paoletti F, D'Avino A, Ciccarelli N, Sidella L, Murri R, Fortuna S, Vullo V, Cauda R, De Luca A, Di Giambenedetto S (2014) Safety and efficacy of treatment switch to raltegravir plus tenofovir/emtricitabine or abacavir/lamivudine in patients with optimal virological control: 48-week results from a randomized pilot study (Raltegravir Switch for Toxicity or Adverse Events, RASTA Study). Scan J Infect Dis 46:34–45.  https://doi.org/10.3109/00365548.2013.840920 CrossRefGoogle Scholar
  15. 15.
    Suzuki A, Uehara Y, Saita M, Inui A isonuma H, Naito T (2016) Raltegravir and abacavir/lamivudine in Japanese treatment-naive and treatment experienced patients with HIV infection: a 48-week retrospective pilot analysis. Jpn J Infect Dis 69:33–38.  https://doi.org/10.7883/yoken.JJID.2014.236 CrossRefPubMedGoogle Scholar
  16. 16.
    Galli L, Poli A, Muccini C, Galizzi N, Danise A, Spagnuolo V, Gianotti N, Carini E, Lazzarin A, Castagna A (2018) An observational, retrospective analysis evaluating switching to raltegravir plus abacavir/lamivudine in HIV-1-infected patients: the ORASWIRAL study. Infect Dis 50(3):220–222.  https://doi.org/10.1080/23744235.2017.1374552 CrossRefGoogle Scholar
  17. 17.
    Troya J, Montejano R, Ryan P, Gómez C, Matarranz M, Cabello A, Vera F, Sepúlveda MA, Santos I, Samperiz G, Bachiller P, Boix V, Barrufet P, Cervero M, Sanz J, Solís J, Yllescas M, Valencia E, GESIDA-8715 Study Group (2018) Raltegravir plus abacavir/lamivudine in virologically suppressed HIV-1-infected patients: 48-week results of the KIRAL study. PLoS One 13(6):e0198768.  https://doi.org/10.1371/journal.pone.0198768 CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Brian J, Collier A, Kharasch E, Whittington D, Thummel KE, Unadkat JD (2011) Complex drug interactions of HIV protease inhibitors 1: inactivation, induction, and inhibition of cytochrome P450 3A by ritonavir or nelfinavir. Drug Metab Dispos 39(6):1070–1078.  https://doi.org/10.1124/dmd.110.037523 CrossRefGoogle Scholar
  19. 19.
    Arribas JR, Pialoux G, Gathe J, Di Perri G, Reynes J, Tebas P, Nguyen T, Ebrahimi R, White K, Piontkowsky D (2014) Simplification to coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus continuation of ritonavir-boosted protease inhibitor with emtricitabine and tenofovir in adults with virologically suppressed HIV (STRATEGY-PI): 48 week results of a randomised, open-label, phase 3b, non-inferiority trial. Lancet Infect Dis 14(7):581–589.  https://doi.org/10.1016/S1473-3099(14)70782-0 CrossRefPubMedGoogle Scholar
  20. 20.
    Ward D, Grant R (2012) Rilpivirine/tenofovir/emtricitabine fixed-dose combination is an efficacious and well-tolerated “switch” regimen for patients on therapy. J Int AIDS Soc 15(4):S18351.  https://doi.org/10.7448/IAS.15.6.18351 CrossRefGoogle Scholar
  21. 21.
    Arae H, Tateyama M, Nakamura H, Tasato D, Kami K, Miyagi K, Maeda S, Uehara H, Moromi M, Nakamura K, Fujita J (2016) Evaluation of the lipid concentrations after switching from antiretroviral drug tenofovir disoproxil fumarate/emtricitabine to abacavir sulfate/lamivudine in virologically-suppressed human immunodeficiency virus-infected patients. Intern Med 55(23):3435–3440.  https://doi.org/10.2169/internalmedicine.55.7518 CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Fontas E, Van Leth F, Sabin CA, Friis-Møller N, Rickenbach M, d'Arminio Monforte A, Kirk O, Dupon M, Morfeldt L, Mateu S, Petoumenos K, El-Sadr W, de Wit S, Lundgren JD, Pradier C, Reiss P, D:A:D Study Group (2004) Lipid profiles in HIV-infected patients receiving combination antiretroviral therapy: are different antiretroviral drugs associated with different lipid profiles? J Infect Dis 189:1056–1074.  https://doi.org/10.1086/381783 CrossRefPubMedGoogle Scholar
  23. 23.
    Krikke M, Tesselaar K, van den Berk GEL, Otto SA, Freriks LH, van Lelyveld SFL, Visseren FJL, Hoepelman AIM, Arends JE (2018) The effect of switching protease inhibitors to raltegravir on endothelial function, in HIV-infected patients. HIV Clin Trials 19(2):75–83.  https://doi.org/10.1080/15284336.2018 CrossRefPubMedGoogle Scholar
  24. 24.
    Casado JL, Santiuste C, Vivancos MJ, Monsalvo M, Moreno A, Perez-Elías MJ, Del Rey JM, Moreno S (2018) Switching to abacavir versus use of a nucleoside-sparing dual regimen for HIV-infected patients with tenofovir-associated renal toxicity. HIV Med.  https://doi.org/10.1111/hiv.12630 CrossRefGoogle Scholar
  25. 25.
    Cattaneo D, Andreoni M, Carosi G, Cauda R, Lazzarin A, Rizzardini G (2017) Generic antiretrovirals for the treatment of HIV: a novel challenge for Western countries? Int J Clin Pharmacol Ther 55(5):381–393.  https://doi.org/10.5414/CP202775 CrossRefPubMedGoogle Scholar
  26. 26.
    Hill A, Hill T, Jose S, Pozniak A (2014) Predicted savings to the UK National Health Service from switching to generic antiretrovirals, 2014-2018. J Int AIDS Soc 17(4 Suppl3):19497.  https://doi.org/10.7448/IAS.17.4.19497 CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2018

Authors and Affiliations

  • Jesús Troya
    • 1
    • 2
    Email author
  • Pablo Ryan
    • 1
    • 2
  • Rocío Montejano
    • 3
  • Alfonso Cabello
    • 4
  • Guillermo Cuevas
    • 1
  • Mariano Matarranz
    • 1
  • Irene Cañamares
    • 1
  • Javier Solís
    • 1
  • Luis Álvarez-Sala Walther
    • 2
    • 5
  1. 1.Hospital Universitario Infanta LeonorMadridSpain
  2. 2.School of MedicineUniversidad Complutense de MadridMadridSpain
  3. 3.Hospital Universitario La PazMadridSpain
  4. 4.Hospital Fundación Jiménez DíazMadridSpain
  5. 5.Hospital Universitario Gregorio MarañónMadridSpain

Personalised recommendations